A previous study showed that blocking the activity of EP3 ameliorates the effects of PGE2 in impairing hippocampal presynaptic plasticity and identified EP3 as a potential therapeutic target for AD (Maingret et al., 2017) and another study showed that EP3 is critical for the phosphorylation of tau (Guan and Wang, 2018). This evidence concerns the gene PTGER3 and Alzheimer disease.